CL2015000382A1 - Composición farmacéutica que comprende al menos un agente farmacéutico activable capaz de causar un cambio celular predeterminado y un aditivo con efecto terapéutico; uso para tratar un trastorno de proliferación celular tal como cancer. (divisional solicitud n° 997-2008). - Google Patents

Composición farmacéutica que comprende al menos un agente farmacéutico activable capaz de causar un cambio celular predeterminado y un aditivo con efecto terapéutico; uso para tratar un trastorno de proliferación celular tal como cancer. (divisional solicitud n° 997-2008).

Info

Publication number
CL2015000382A1
CL2015000382A1 CL2015000382A CL2015000382A CL2015000382A1 CL 2015000382 A1 CL2015000382 A1 CL 2015000382A1 CL 2015000382 A CL2015000382 A CL 2015000382A CL 2015000382 A CL2015000382 A CL 2015000382A CL 2015000382 A1 CL2015000382 A1 CL 2015000382A1
Authority
CL
Chile
Prior art keywords
cancer
treat
additive
causing
cell proliferation
Prior art date
Application number
CL2015000382A
Other languages
English (en)
Inventor
Frederic A Bourke
Original Assignee
Inmunolight Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39827110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000382(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inmunolight Llc filed Critical Inmunolight Llc
Publication of CL2015000382A1 publication Critical patent/CL2015000382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/008—Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0656—Chemical light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2015000382A 2007-04-08 2015-02-17 Composición farmacéutica que comprende al menos un agente farmacéutico activable capaz de causar un cambio celular predeterminado y un aditivo con efecto terapéutico; uso para tratar un trastorno de proliferación celular tal como cancer. (divisional solicitud n° 997-2008). CL2015000382A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91066307P 2007-04-08 2007-04-08
US11/935,655 US9358292B2 (en) 2007-04-08 2007-11-06 Methods and systems for treating cell proliferation disorders

Publications (1)

Publication Number Publication Date
CL2015000382A1 true CL2015000382A1 (es) 2015-04-24

Family

ID=39827110

Family Applications (3)

Application Number Title Priority Date Filing Date
CL200800997A CL2008000997A1 (es) 2007-04-08 2008-04-07 Metodo de tratamiento que comprende administrar un agente farmaceutico activable con capacidad de efectuar un cambio celular al activarse, aplicar una energia iniciadora, donde el cambio celular trata el trastorno de proliferacion celular; metodo de
CL2015000383A CL2015000383A1 (es) 2007-04-08 2015-02-17 Kit farmaceutico que comprende al menos un agente farmaceutico activable capaz de causar un cambio celular predeterminado y por lo menos un agente modulador de la energía capaz de activar el agente farmaceutico.
CL2015000382A CL2015000382A1 (es) 2007-04-08 2015-02-17 Composición farmacéutica que comprende al menos un agente farmacéutico activable capaz de causar un cambio celular predeterminado y un aditivo con efecto terapéutico; uso para tratar un trastorno de proliferación celular tal como cancer. (divisional solicitud n° 997-2008).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL200800997A CL2008000997A1 (es) 2007-04-08 2008-04-07 Metodo de tratamiento que comprende administrar un agente farmaceutico activable con capacidad de efectuar un cambio celular al activarse, aplicar una energia iniciadora, donde el cambio celular trata el trastorno de proliferacion celular; metodo de
CL2015000383A CL2015000383A1 (es) 2007-04-08 2015-02-17 Kit farmaceutico que comprende al menos un agente farmaceutico activable capaz de causar un cambio celular predeterminado y por lo menos un agente modulador de la energía capaz de activar el agente farmaceutico.

Country Status (12)

Country Link
US (5) US9358292B2 (es)
EP (2) EP3299031B1 (es)
JP (1) JP2010523690A (es)
KR (6) KR102065832B1 (es)
CN (2) CN101711246B (es)
AR (1) AR066899A1 (es)
AU (1) AU2008237121B2 (es)
CA (2) CA2935870C (es)
CL (3) CL2008000997A1 (es)
IN (2) IN2015DN03080A (es)
TW (2) TWI654008B (es)
WO (1) WO2008124681A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951561B2 (en) 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US8383836B2 (en) 2009-04-21 2013-02-26 Duke University Methods and systems for treating cell proliferation disorders with psoralen derivatives
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US9488916B2 (en) 2007-04-08 2016-11-08 Immunolight, Llc. Interior energy-activation of photo-reactive species inside a medium or body
US20090104212A1 (en) * 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
US9662389B2 (en) * 2008-03-31 2017-05-30 Duke University Functionalized metal-coated energy converting nanoparticles, methods for production thereof and methods for use
US9907976B2 (en) 2011-07-08 2018-03-06 Immunolight, Llc Phosphors and scintillators for light stimulation within a medium
CA2906990A1 (en) * 2008-04-04 2009-10-08 Duke University Non-invasive systems and methods for in-situ photobiomodulation
US8770203B2 (en) 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders
US20100260677A1 (en) * 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
WO2010123993A1 (en) * 2009-04-21 2010-10-28 Tuan Vo-Dinh Non-invasive energy upconversion methods and systems for in-situ photobiomodulation
WO2010144531A1 (en) * 2009-06-09 2010-12-16 Gary Wayne Jones Method for selective photodynamic therapy and light source for implementation thereof
CN102870235B (zh) * 2009-11-10 2016-11-23 免疫之光有限责任公司 用于从包括用于上变频的射频、微波能量和磁感应源的各种能量源产生发射光的上下变频系统
PT3213738T (pt) 2010-08-27 2020-03-31 Sebacia Inc Composições e métodos para modulação térmica direcionada
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
US20130012754A1 (en) * 2011-07-07 2013-01-10 Empire Technology Development Llc Microwave induced photodynamic therapy
AU2013329450B2 (en) 2012-10-11 2017-06-22 Coronado Aesthetics, Llc Silver nanoplate compositions and methods
KR101536325B1 (ko) * 2013-10-16 2015-07-14 주식회사 지니스 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
WO2015112850A2 (en) * 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
EP3838904A1 (en) 2014-06-19 2021-06-23 Immunolight, LLC Methods and systems for treating cell proliferation disorders with psoralen derivatives
US11534622B2 (en) * 2014-08-18 2022-12-27 Immunolight, Llc Non-invasive systems and methods for selective activation of photoreactive responses
US10383939B2 (en) 2015-03-20 2019-08-20 The Regents Of The University Of Colorado, A Body Corporate Light-activated compositions and methods using the same
WO2016154017A1 (en) * 2015-03-20 2016-09-29 Sienna Biopharmaceuticals, Inc. Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles
CN108348624B (zh) * 2015-08-04 2021-07-27 瓦克星治疗有限责任公司 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法
US10407399B2 (en) 2015-09-01 2019-09-10 Howard Hughes Medical Institute Ion-activated photolabile compounds
JP6966478B2 (ja) 2016-02-02 2021-11-17 イミュノライト・エルエルシー フォスファー含有薬剤活性化剤、その懸濁液、懸濁液を含むシステム、及び使用方法
EP3448292A4 (en) * 2016-04-25 2020-04-08 Immunolight, Llc. INSERTING DEVICES AND SYSTEMS FOR PRODUCING EMITTED LIGHT INSIDE A MEDIUM AND METHOD FOR USE THEREOF
AU2017384425B2 (en) * 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
CA3131865A1 (en) 2019-03-04 2020-09-10 Immunolight, Llc. Energy augment structures for use with energy emitters and collectors
CN110115761B (zh) * 2019-05-09 2023-06-16 英诺激光科技股份有限公司 一种利用激光和载体技术制备疫苗的方法
CA3188659A1 (en) * 2020-06-30 2022-04-07 Board Of Regents, The University Of Texas System Cancer radiosensitization by in situ formation of gold nanoparticles and/or gold nanoclusters
US20220096634A1 (en) 2020-09-30 2022-03-31 David A. Jernigan Method of manipulating phages within the body to attack infectious target cells
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
CN115414354A (zh) * 2022-08-29 2022-12-02 西南医科大学 花椒毒素在制备治疗血小板减少症药物中的应用
CN116925997B (zh) * 2023-07-27 2024-04-02 湖北医药学院 左氧氟沙星在制备促进细胞增殖中的药物的用途

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124A (en) 1837-02-10 Improvement in the machine for weighing heavy bodies
US7045A (en) 1850-01-22 Chitck foe
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4748120A (en) 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5091385A (en) 1988-09-30 1992-02-25 Baylor Research Institute Pre-activated therapeutic agents derived from photoactive compounds
US5177073A (en) * 1988-09-30 1993-01-05 Baylor Research Institute Therapeutic compositions derived from photoactive compounds
US5216176A (en) 1989-01-23 1993-06-01 Lehigh University 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor
US4979935A (en) * 1989-02-21 1990-12-25 Quantex Corporation Method of photodynamic therapy employing electron trapping material
US5658722A (en) * 1990-05-15 1997-08-19 New York Blood Center, Inc. Process for the sterilization of biological compositions using UVA1 irradiation
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6204058B1 (en) * 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
US6669965B2 (en) * 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
JPH08505054A (ja) 1992-12-23 1996-06-04 アイオア ステート ユニバーシティー リサーチ ファンデーション インコーポレーテッド 分子フラッシュ
US5728590A (en) * 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
US6121425A (en) * 1994-07-29 2000-09-19 Nanoprobes, Inc. Metal-lipid molecules
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US6235508B1 (en) 1995-06-07 2001-05-22 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
IT1275571B (it) * 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
JP3689939B2 (ja) 1995-07-28 2005-08-31 豊田合成株式会社 光触媒装置
US20030022105A1 (en) * 1995-09-06 2003-01-30 Paras N. Prasad Two -photon upconverting dyes and applications
ES2251020T3 (es) 1996-03-29 2006-04-16 Therakos, Inc. Tratamiento por fotoferesis de infecciones por hcv cronicas.
AU710242B2 (en) 1996-03-29 1999-09-16 Therakos, Inc. Photopheresis treatment of leukocytes
JPH09299937A (ja) 1996-05-09 1997-11-25 Daikin Ind Ltd 被処理体処理装置
US7390668B2 (en) * 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US5957960A (en) * 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells
US6071944A (en) * 1997-11-12 2000-06-06 Bowling Green State University Method of treatment of pigmented cancer cells utilizing photodynamic therapy
US20030022170A1 (en) * 1998-03-06 2003-01-30 Millenium Pharmaceuticals, Inc. Novel fibroblast growth factors and therapeutic and diagnostic uses therefor
US6075155A (en) 1998-06-22 2000-06-13 Rensselaer Polytechnic Institute Radiation-curable cycloaliphatic epoxy compounds, uses thereof, and compositions containing them
US6645464B1 (en) * 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
US7045124B1 (en) * 1999-01-12 2006-05-16 Vasogen Irelend Limited Pre-conditioning against cell death
US6132958A (en) * 1999-05-27 2000-10-17 The Rockefeller University Fluorescent bead for determining the temperature of a cell and methods of use thereof
US7332344B2 (en) 1999-12-01 2008-02-19 Photonic Research Systems Limited Luminescence assays
WO2001047438A1 (en) 1999-12-23 2001-07-05 Edwards Lifesciences Corporation Enhanced visualization of medical implants
US6719778B1 (en) * 2000-03-24 2004-04-13 Endovascular Technologies, Inc. Methods for treatment of aneurysms
CN1308961A (zh) 2001-02-16 2001-08-22 北京飞天兆业科技有限责任公司 一种光化学疗法治疗皮肤病用的药物
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US7364872B1 (en) * 2001-03-30 2008-04-29 Nanoprobes Test methods using enzymatic deposition and alteration of metals
JP2004532245A (ja) 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
US7008559B2 (en) * 2001-06-06 2006-03-07 Nomadics, Inc. Manganese doped upconversion luminescence nanoparticles
US7303578B2 (en) 2001-11-01 2007-12-04 Photothera, Inc. Device and method for providing phototherapy to the brain
GB0126236D0 (en) 2001-11-01 2002-01-02 Univ East Anglia Photosensitiser functionalised nanoparticles
EP1465699A4 (en) 2001-12-12 2006-05-24 Leon J Lewandowski AUTOIMMUNE STIMULATION BY PHOTOPHORESIS
WO2003057238A1 (en) * 2001-12-28 2003-07-17 Oregon Health & Science University Agents that recognize src when phosphorylated at serine 17
US6908591B2 (en) 2002-07-18 2005-06-21 Clearant, Inc. Methods for sterilizing biological materials by irradiation over a temperature gradient
CA2505603A1 (en) * 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
US7695738B2 (en) * 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
KR20060092254A (ko) 2003-09-23 2006-08-22 라이트 사이언시즈 코포레이션 표적화된 ｐｄｔ 제제의 선택성을 증진시키는 표적 결합에의해 활성화된 일중항 산소 감광제
US20060067941A1 (en) * 2003-12-05 2006-03-30 Secretary, Department Of Health & Human Services Nanotubes for cancer therapy and diagnostics
EP1696957A2 (en) 2003-12-17 2006-09-06 Philips Intellectual Property & Standards GmbH Radiation therapy and medical imaging using uv emitting nanoparticles
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
WO2006037081A2 (en) * 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
JPWO2006038449A1 (ja) 2004-10-05 2008-07-31 日本板硝子株式会社 蛍光体微粒子が分散した発光体とその製造方法、およびこの発光体を含む材料または物品
FR2877571B1 (fr) * 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
NZ544247A (en) 2004-12-22 2007-06-29 Omj Ireland Ltd Phototherapy using psoralen derivatives and a UVB absorber
US7397043B2 (en) * 2005-01-26 2008-07-08 Nomadics, Inc. Standoff optical detection platform based on surface plasmon-coupled emission
US7538329B2 (en) * 2005-02-02 2009-05-26 Nomadics, Inc. Energy-transfer nanocomposite materials and methods of making and using same
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
JP2008535760A (ja) * 2005-04-06 2008-09-04 ドレクセル ユニバーシティー 機能性ナノ粒子充填カーボンナノチューブおよびその製造のための方法
IL168184A (en) 2005-04-21 2011-11-30 Univ Ariel Res & Dev Co Ltd Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy
EP1779891A1 (en) 2005-10-28 2007-05-02 Abdula Kurkayev Method of activating a photosensitizer
EP2003228A2 (en) 2006-03-22 2008-12-17 Kiichirou Sumi Process for producing metal coating material and metal coating material
US20070243137A1 (en) * 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
GB0712287D0 (en) 2007-06-22 2007-08-01 Ucl Business Plc Antimicrobial Conjugates
US8328785B2 (en) * 2006-09-18 2012-12-11 The University Of Houston System Use of nanoparticles in the photodynamic treatment of tumors
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US8951561B2 (en) * 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
WO2017070197A1 (en) * 2015-10-19 2017-04-27 Immunolight, Llc X-ray psoralen activated cancer therapy (x-pact)
US20090104212A1 (en) 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
US8236239B2 (en) 2007-11-16 2012-08-07 Bernstein Eric F Sterilizing compositions comprising phosphors for converting electromagnetic radiation to UVC radiation and methods for using the same
US8431041B2 (en) 2008-03-31 2013-04-30 Stc.Unm Halide-based scintillator nanomaterial
CA2906990A1 (en) * 2008-04-04 2009-10-08 Duke University Non-invasive systems and methods for in-situ photobiomodulation
US8770203B2 (en) * 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders
WO2015112850A2 (en) * 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

Also Published As

Publication number Publication date
CN104027809A (zh) 2014-09-10
EP3299031B1 (en) 2022-06-08
TW201519929A (zh) 2015-06-01
KR20170127045A (ko) 2017-11-20
JP2010523690A (ja) 2010-07-15
KR20170067904A (ko) 2017-06-16
KR20140141725A (ko) 2014-12-10
KR20170015570A (ko) 2017-02-08
US20140242035A1 (en) 2014-08-28
WO2008124681A4 (en) 2009-12-23
TWI654008B (zh) 2019-03-21
US10398777B2 (en) 2019-09-03
IN2015DN03080A (es) 2015-10-02
EP3299031A1 (en) 2018-03-28
US9682146B2 (en) 2017-06-20
US20140341845A1 (en) 2014-11-20
CN101711246B (zh) 2014-06-25
KR20200001607A (ko) 2020-01-06
AU2008237121B2 (en) 2013-10-10
TWI530308B (zh) 2016-04-21
CA2935870A1 (en) 2008-10-16
KR101925176B1 (ko) 2018-12-04
WO2008124681A3 (en) 2009-02-05
CA2935870C (en) 2021-07-20
AR066899A1 (es) 2009-09-23
US9358292B2 (en) 2016-06-07
CN101711246A (zh) 2010-05-19
US20190336605A1 (en) 2019-11-07
US20080248001A1 (en) 2008-10-09
US11103580B2 (en) 2021-08-31
CA2682686C (en) 2016-12-20
EP2150549A4 (en) 2014-09-03
TW200902114A (en) 2009-01-16
KR20100022951A (ko) 2010-03-03
CL2008000997A1 (es) 2008-10-03
AU2008237121A1 (en) 2008-10-16
CA2682686A1 (en) 2008-10-16
US9352040B2 (en) 2016-05-31
WO2008124681A2 (en) 2008-10-16
IN2015DN03077A (es) 2015-10-02
EP2150549A2 (en) 2010-02-10
KR102065832B1 (ko) 2020-01-13
CL2015000383A1 (es) 2015-04-24
US20170258908A1 (en) 2017-09-14
CN104027809B (zh) 2017-08-25

Similar Documents

Publication Publication Date Title
CL2015000382A1 (es) Composición farmacéutica que comprende al menos un agente farmacéutico activable capaz de causar un cambio celular predeterminado y un aditivo con efecto terapéutico; uso para tratar un trastorno de proliferación celular tal como cancer. (divisional solicitud n° 997-2008).
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CL2012002844A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende; y su uso en el tratamiento de un trastorno proliferativo de celulas tal como cancer (divisional solicitud nº 311-07).
BR112013006331A2 (pt) composições de fulvestranto e métodos de uso
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
CL2008001334A1 (es) Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
DOP2010000280A (es) Compuestos heterociclicos novedosos y usos de los mismos
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CL2007001995A1 (es) Compuestos derivados de pirrolotriazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el cancer.
CL2008002307A1 (es) Uso de un agente farmaceutico activable por un proceso de absorcion de dos fotones simultaneo, que efectua un cambio celular predeterminado cuando se activa y es util para tratar un trastorno de proliferacion celular.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2008003061A1 (es) Compuestos tienopirimidina y pirazolopirimidina, inhibidores de quinasa mtor y quinasa pi3; composicion farmaceutica que comprende a dichos compuesto; y su uso para tratar aterosclerosis, artritis, cancer, entre otras enfermedades.
GT200300245A (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CL2008001943A1 (es) Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
BRPI1010903A2 (pt) partícula modificada na superfície, composição farmacêutica, método para intensificar a absorção celular de um agente ativo, uso de uma pluralidade de partículas modificadas na superfície, e, pluralidade de partículas modificadas na superfície